Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study

The relationship between gains in bone mineral density (BMD) in the hip and the incidence of vertebral fractures in the MOVER study was examined. Japanese patients from the ibandronate and risedronate treatment groups whose hip BMD had increased during the 3-year treatment period were classified int...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Calcif Tissue Int
Κύριοι συγγραφείς: Hagino, Hiroshi, Yoshida, Seitaro, Hashimoto, Junko, Matsunaga, Masayuki, Tobinai, Masato, Nakamura, Toshitaka
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Springer US 2014
Θέματα:
Original Research
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4239781/
https://ncbi.nlm.nih.gov/pubmed/25377907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00223-014-9927-7
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια